How Does Upneeq Work? A Temporary Lift for Acquired Ptosis

Upneeq is a prescription eye drop that temporarily raises a drooping upper eyelid. Its active ingredient, oxymetazoline, stimulates alpha-adrenergic receptors in Müller’s muscle—a small accessory muscle that helps hold the upper lid open. When that muscle contracts, the eyelid lifts.

In the United States, Upneeq is approved for acquired blepharoptosis in adults. “Acquired” means the lid began drooping later in life rather than being present from birth. The labeled dose is one drop in one or both affected eyes once daily, according to the current FDA labeling on DailyMed.

What the drop changes—and what it does not

Upneeq activates an eyelid muscle; it does not permanently repair the structure that caused the droop. For example, it does not tighten a stretched levator tendon, remove excess eyelid skin or provide the lasting anatomical correction that surgery may offer. Its lifting effect is temporary.

This distinction matters because not every low-looking lid is the type of ptosis Upneeq treats. Loose skin can hang over an otherwise normally positioned eyelid, while swelling, a mass or a nerve or muscle disorder can also make a lid appear low. An eye-care professional needs to identify the cause before deciding whether this drop fits.

How quickly does Upneeq work?

The lift can begin within minutes, although the amount varies. In one of the two randomized phase 3 trials, average upper-lid height increased by about 0.6 mm at five minutes and 0.9 mm at 15 minutes after the first dose. The vehicle-drop group had smaller average changes. Some treated participants had no measurable response.

These early measurements were reported in a later analysis of the two trials, but only one trial collected data at five and 15 minutes. The studies were funded by the manufacturer, and several investigators disclosed financial relationships with it (published trial analysis).

The current label says the maximum average increase in eyelid height occurred at about two hours, with an increase still observed through eight hours. In the approval trials, Upneeq also improved the amount of the upper visual field participants could see compared with vehicle drops (FDA review).

These averages are not a promise of a dramatic “eye lift” or a specific duration for every user. A difference around a millimeter can be noticeable and may uncover part of the pupil, but individual results depend on the severity and cause of the ptosis and how well Müller’s muscle responds.

How to use it safely

Follow the prescriber’s directions rather than adding extra doses for a stronger or longer effect. The FDA label instructs users to:

• Put one drop in one or both affected eyes once daily, as prescribed.
• Remove contact lenses first and wait at least 15 minutes before reinserting them.
• Separate Upneeq and any other eye drop by at least 15 minutes.
• Avoid touching the single-use container tip to the eye or another surface.
• Discard the container immediately after dosing, even if solution remains.
• Keep the containers out of children’s reach; swallowing oxymetazoline products can cause serious harm.

If contacts regularly worsen burning or dryness, address the fit and wearing schedule rather than treating discomfort by layering drops. Our guide to choosing contacts when your eyes are dry explains why lens material alone does not determine comfort.

Side effects and precautions

In controlled trials, adverse reactions reported in 1% to 5% of people included dry eye, eye redness, punctate keratitis (small areas of corneal irritation), blurred vision, pain or irritation when the drop was used, and headache. Upneeq is preservative-free, but that does not mean it cannot irritate the eye or worsen dryness.

Oxymetazoline is an alpha-adrenergic agonist, a drug class that can affect blood pressure. The label advises caution for people with severe or unstable cardiovascular disease, uncontrolled high or low blood pressure, orthostatic hypotension, impaired blood flow to the heart or brain, or Sjögren’s syndrome. It also advises caution with medicines including beta-blockers, blood-pressure drugs, cardiac glycosides and alpha blockers. A prescriber or pharmacist should review the complete medication list.

A new drooping eyelid needs a cause, not just a lift

Do not use a cosmetic improvement to delay evaluation of a new or unexplained droop. The label notes that ptosis can accompany stroke, cerebral aneurysm, Horner syndrome, myasthenia gravis, eye-movement disorders, orbital infection or an orbital mass.

Seek urgent medical assessment for a suddenly drooping lid—particularly with a severe headache, unequal pupils, double vision, difficulty moving an eye, facial or limb weakness, speech trouble, eye pain or a sudden vision change. Upneeq may raise the lid temporarily, but it does not treat any of those underlying conditions.